RIGL Rigel Pharmaceuticals, Inc.

2.39
+0  (0%)
Previous Close 2.39
Open 2.39
Price To book 3.58
Market Cap 236.46M
Shares 98,937,000
Volume 819,751
Short Ratio 3.76
Av. Daily Volume 757,495

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 preliminary data released January 5, 2017. Full data due in 2018.
Fostamatinib
IgA nephropathy
Phase 2 trial did not meet endpoints
R348
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. NDA filing due 1Q 2017.
Fostamatinib
Immune Thrombocytopenic Purpura (ITP)
Phase 2 data from first of two stages due in 2017.
Fostamatinib
Autoimmune hemolytic anemia (AIHA)

Latest News

  1. RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
  2. Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
  3. RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  4. Rigel Announces Pricing Of Public Offering Of Common Stock
  5. RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial
  6. Rigel Announces Proposed Public Offering Of Common Stock
  7. Why the Rigel Pharmaceuticals Update Could Signal Further Growth
  8. Fostamatinib Study Results Continue to Trend Positive
  9. Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  10. Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy
  11. Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy
  12. Is Rigel Pharmaceuticals, Inc. (RIGL) Worthy of Your Portfolio?
  13. Hedge Funds Think The Sky’s The Limit For Horizon Global Corp (HZN)
  14. Rigel to Present at Jefferies 2016 London Healthcare Conference
  15. RIGEL PHARMACEUTICALS INC Financials
  16. ETF’s with exposure to Rigel Pharmaceuticals, Inc. : November 4, 2016
  17. Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016
  18. Edited Transcript of RIGL earnings conference call or presentation 1-Nov-16 9:00pm GMT
  19. RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  20. Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update